Lundbeck head of R&D: "We have cleared the way for opportunity"
After three years leading Lundbeck’s research and development division, Johan Luthman feels that the company is poised to strike, should chance present itself. ”Luck is an important part of our industry,” he says.
by andreas lønstrup, translated by daniel pedersen & catherine brett
With a résumé listing some of the top positions at firms like Eisai, Merck, and Astrazeneca, 61-year-old Swedish national Johan Luthman can hardly be blamed for coming to the Danish pharmaceutical industry with a sense pride, and perhaps limited respect for where he was going, when he joined Lundbeck as head of research and development three years ago.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck hunts for new success drugs in niche diseases
For subscribers
.jpg)
.jpg&w=384&q=75)
